Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy

Despite recent advances, non-Hodgkin’s B cell lymphoma patients often relapse or remain refractory to therapy. Therapeutic resistance is often associated with survival signaling via nuclear factor κB (NF-κB) transcription factor, an attractive but undruggable molecular target. In this study, we desc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Ther
Päätekijät: Zhang, Zhuoran, Zhao, Xingli, Wang, Dongfang, Moreira, Dayson, Su, Yu-Lin, Alcantara, Marice, Swiderski, Piotr, Wong, Jeffrey, Hui, Susanta, Forman, Stephen, Kwak, Larry, Kortylewski, Marcin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Gene & Cell Therapy 2021
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934632/
https://ncbi.nlm.nih.gov/pubmed/33248246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.11.026
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia